(19)
(11) EP 3 430 141 A1

(12)

(43) Date of publication:
23.01.2019 Bulletin 2019/04

(21) Application number: 17710874.3

(22) Date of filing: 14.03.2017
(51) International Patent Classification (IPC): 
C12N 15/113(2010.01)
A61K 31/7125(2006.01)
C07H 21/00(2006.01)
A61P 33/02(2006.01)
 A61K 31/712(2006.01)
A61K 47/50(2017.01)
A61P 37/04(2006.01)
A61P 31/00(2006.01)
(86) International application number:
PCT/EP2017/055925
(87) International publication number:
WO 2017/157899 (21.09.2017 Gazette 2017/38)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 14.03.2016 EP 16160149

(71) Applicant: F. Hoffmann-La Roche AG
4070 Basel (CH)

(72) Inventors:
  • PEDERSEN, Lykke
    2970 Horsholm (DK)
  • JAVANBAKHT, Hassan
    4070 Basel (CH)
  • JACKEROTT, Malene
    2970 Horsholm (DK)
  • OTTOSEN, Søren
    2970 Horsholm (DK)
  • LUANGSAY, Souphalone
    4070 Basel (CH)

(74) Representative: Hansen, Marianne Rudolph et al
F. Hoffmann-La Roche AG Patent Department Grenzacherstrasse 124
4070 Basel
4070 Basel (CH)

   


(54) OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION